U.S. flag

An official website of the United States government

NM_000251.3(MSH2):c.97A>C (p.Thr33Pro) AND Malignant tumor of breast

Germline classification:
Uncertain significance (1 submission)
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001354855.3

Allele description [Variation Report for NM_000251.3(MSH2):c.97A>C (p.Thr33Pro)]

NM_000251.3(MSH2):c.97A>C (p.Thr33Pro)

Gene:
MSH2:mutS homolog 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2p21
Genomic location:
Preferred name:
NM_000251.3(MSH2):c.97A>C (p.Thr33Pro)
HGVS:
  • NC_000002.12:g.47403288A>C
  • NG_007110.2:g.5165A>C
  • NM_000251.3:c.97A>CMANE SELECT
  • NM_001258281.1:c.-30-72A>C
  • NP_000242.1:p.Thr33Pro
  • NP_000242.1:p.Thr33Pro
  • LRG_218t1:c.97A>C
  • LRG_218:g.5165A>C
  • LRG_218p1:p.Thr33Pro
  • NC_000002.11:g.47630427A>C
  • NM_000251.1:c.97A>C
  • NM_000251.2:c.97A>C
  • P43246:p.Thr33Pro
  • p.T33P
Protein change:
T33P
Links:
UniProtKB: P43246#VAR_043738; dbSNP: rs63751107
NCBI 1000 Genomes Browser:
rs63751107
Molecular consequence:
  • NM_001258281.1:c.-30-72A>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000251.3:c.97A>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Malignant tumor of breast
Synonyms:
Malignant breast neoplasm; Cancer breast
Identifiers:
MONDO: MONDO:0007254; MedGen: C0006142

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001549568Department of Pathology and Laboratory Medicine, Sinai Health System - The Canadian Open Genetics Repository (COGR)

See additional submitters

no assertion criteria provided
Uncertain significanceunknownclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownyesnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Department of Pathology and Laboratory Medicine, Sinai Health System - The Canadian Open Genetics Repository (COGR), SCV001549568.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The MSH2 p.Thr33Pro variant was identified in 3 of 2424 proband chromosomes (frequency: 0.001) from individuals with colon and endometrial cancer (Hegde 2005, Hampel 2006, Chubb 2015). The variant was identified in dbSNP (rs63751107) as “with uncertain significance allele”, ClinVar (classified as "uncertain significance" by Invitae, GeneDx and five other submitters) and UMD-LSDB (observed 2x). The variant was identified in control databases in 14 of 248,976 chromosomes at a frequency of 0.00006 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Latino in 4 of 31,200 chromosomes (freq: 0.0001), European in 10 of 113,324 chromosomes (freq: 0.00009), but not in the African, Other, Ashkenazi Jewish, East Asian, Finnish, and South Asian populations. A cell line derived from a patient with the observed variant had normal levels of MSH2 and MSH6 protein as observed on a western blot (Ollila 2006). In an in vitro mismatch repair assay, the variant was generated by site-directed mutagenesis and decreased MMR efficiency by 23% compared to wild type (Ollila 2006). The variant is present in the DNA binding domain of MSH2 and in another study was demonstrated to bind mismatches as efficiently as wild type, and had a slightly reduced DNA release. These observations led to the conclusion that the variant causes a slight defect in MMR efficiency, and based on these experiments, it is unclear if the variant is pathogenic (Ollila 2008). The p.Thr33 residue is conserved across mammals and other organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 16, 2024